Ticaros

Biotech · KR

Developer of CAR-T immunotherapy treatments for blood cancer (TC011)

Funding history

Date	Round	Amount
Mar 2026	Series D Plus Ticaros raised KRW 20.8 billion (~$14.6M) in Series D funding to accelerate Phase 2 trials of its CAR-T therapy TC011.	$14.6M